Retatrutide
Triple agonist (GIP/GLP-1/glucagon) studied for weight and glycemic control.
Overview
High interest in metabolic research; titration and monitoring mirror class norms.
What it is
Synthetic peptide triple incretin/glucagon agonist.
Mechanism (high level)
Combined incretin and glucagon receptor activity with class GI and heart-rate signals in trials.
Quick facts
- Dosage
- Per trial or future label
- Route
- Subcutaneous
- Cycle
- Weekly titration patterns in studies
- Storage
- Per manufacturer
Research indications
- Obesity and T2D trial programs
Research protocols (education)
Education-first logging template
Use PepTok to track adherence and notes; any protocol must be directed by a qualified clinician.
Interactions
Often avoided with
- Other GLP-1 agents without specialist approval
Often combined with
- Hydration and gradual dose escalation when prescribed
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- Nausea, vomiting, gallbladder disease — urgent care for severe abdominal pain.
Regulatory notes
- Regulatory status evolves; follow prescribing information when available.
FAQ
Is this a prescription?
PepTok does not provide prescriptions; it is for logging and education.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.